Buspirone as a Potential Treatment for Recurrent Central Apnea

Stopped early · Phase 3

Conditions studied: Central Apnea, Heart Failure

In brief

The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients with Heart Failure.

Key facts

Study ID

NCT00746954

Run by

VA Office of Research and Development

People needed

8

Starts

2008-09-01

Expected to finish

2011-12-01

Last updated by the study team

2016-03-14

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide informed consent,
• Ambulatory and in stable condition for the past 4 months,
• A diagnosis of heart failure with left ventricular systolic dysfunction as evidenced by an ejection fraction <35%,
• NYHA class II or III clinical status, and
• Diagnosis of dilated cardiomyopathy or ischemic cardiomyopathy.

You may not qualify if…

• Unstable angina, unstable heart failure, acute pulmonary edema, congenital heart disease
• History of unstable and/or advanced hepatic disease
• History of renal failure, CrCL < 30
• Current use of an SSRI, or use within one month of testing
• Intrinsic pulmonary diseases: ILD and/or COPD (FEV1/FVC < 65%)
• Kyphoscoliosis or neuromuscular disease
• Suboptimally treated hypothyroidism
• Use of narcotics or benzodiazepines
• Use of theophylline or pseudoephedrine
• Use the following medications:
• MAO inhibitors
• diazepam
• haloperidol
• nefazodone
• trazodone
• erythromycin
• grapefruit juice
• itraconazole
• rifampin
• ketoconazole
• ritonavir,
• cimetidine
• Known allergy to buspirone or acetazolamide

Where it is running

• VA Medical Center, Cleveland — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.